Schedule of Operations by Reportable Segment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Revenue	$ 30,258,000	$ 47,307,000
Interest expense	553,000	126,000
Interest Income	1,289,000	629,000
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	30,258,000	47,307,000
Assets held for sale	51,595,000
Depreciation and amortization	5,206,000	11,463,000
Cost of revenue	26,647,000	40,247,000
Interest expense	4,812,000	126,000
Interest Income	1,289,000
Stock based compensation		4,000
Net income (loss) from continuing operations	(97,503,000)	(69,662,000)
Capital expenditures	818,000	2,294,000
Identifiable assets	153,192,000	248,915,000
Operating Segments [Member] | Product Packaging [Member]
Segment Reporting Information [Line Items]
Revenue	18,497,000	17,973,000
Assets held for sale
Depreciation and amortization	761,000	715,000
Cost of revenue	15,282,000	16,960,000
Interest expense	185,000	140,000
Interest Income
Stock based compensation		1,000
Net income (loss) from continuing operations	327,000	(1,234,000)
Capital expenditures	689,000	1,612,000
Identifiable assets	21,508,000	24,641,000
Operating Segments [Member] | Commercial Banking [Member]
Segment Reporting Information [Line Items]
Revenue	385,000	764,000
Assets held for sale
Depreciation and amortization
Cost of revenue	1,139,000	1,041,000
Interest expense
Interest Income
Stock based compensation
Net income (loss) from continuing operations	(31,497,000)	(459,000)
Capital expenditures
Identifiable assets	12,285,000	48,240,000
Operating Segments [Member] | Direct Marketing Online Sales [Member]
Segment Reporting Information [Line Items]
Revenue	6,088,000	21,989,000
Assets held for sale
Depreciation and amortization	157,000	413,000
Cost of revenue	2,075,000	9,828,000
Interest expense	(5,000)	1,000
Interest Income	986,000
Stock based compensation
Net income (loss) from continuing operations	(32,860,000)	(40,182,000)
Capital expenditures	4,000	384,000
Identifiable assets	6,303,000	27,526,000
Operating Segments [Member] | Biotechnology [Member]
Segment Reporting Information [Line Items]
Revenue
Assets held for sale
Depreciation and amortization	1,163,000	1,113,000
Cost of revenue	77,000
Interest expense
Interest Income	155,000
Stock based compensation
Net income (loss) from continuing operations	(7,168,000)	(7,462,000)
Capital expenditures	17,000	276,000
Identifiable assets	49,305,000	53,069,000
Operating Segments [Member] | Securities [Member]
Segment Reporting Information [Line Items]
Revenue	5,288,000	6,581,000
Assets held for sale	51,595,000
Depreciation and amortization	3,047,000	9,093,000
Cost of revenue	8,003,000	11,784,000
Interest expense	4,632,000	(15,000)
Interest Income	148,000
Stock based compensation
Net income (loss) from continuing operations	(19,792,000)	(8,238,000)
Capital expenditures	104,000	18,000
Identifiable assets	59,345,000	83,873,000
Operating Segments [Member] | Corporate Segment [Member]
Segment Reporting Information [Line Items]
Revenue
Assets held for sale
Depreciation and amortization	78,000	129,000
Cost of revenue	71,000	634,000
Interest expense
Interest Income
Stock based compensation		3,000
Net income (loss) from continuing operations	(6,513,000)	(12,084,000)
Capital expenditures	4,000	4,000
Identifiable assets	$ 4,446,000	$ 11,566,000